Nkar­ta to lay off 34% of staff; Savara’s debt fi­nanc­ing deal

Plus, news about Bi­cy­cle Ther­a­peu­tics, Kel­so Phar­ma, Ar­bu­tus Bio­phar­ma, As­cle­tis Phar­ma, Alvotech and Xbrane:

Nkar­ta ax­es 34% of staff: The cell ther­a­py mak­er

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER